Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer

Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK‐positive advanced non‐small cell lung cancer (NSCLC). In the phase I/II study (NCT01970865), potential exposure‐response (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Joseph, Ruiz‐Garcia, Ana, James, Leonard P., Peltz, Gerson, Thurm, Holger, Clancy, Jill, Hibma, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290079/
https://www.ncbi.nlm.nih.gov/pubmed/33973232
http://dx.doi.org/10.1002/cpt.2228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290079/
https://www.ncbi.nlm.nih.gov/pubmed/33973232
http://dx.doi.org/10.1002/cpt.2228

Ejemplares similares